Neurology & Clinical Pharmacology
Carbamazepine (Tegretol)
Carbamazepine (trade name Tegretol, as well as generic forms available in Canada) is an antiepileptic of the iminostilbene class whose clinical use dates back to the 1960s. It acts primarily by blocking voltage-dependent sodium channels in their inactivated state, thereby reducing the discharge frequency of hyperexcitable neurons without altering normal action potentials - a mechanism which explains its efficacy in focal (partial) epilepsy and paroxysmal neuropathic pain such as trigeminal neuralgia. Carbamazepine is also used as a mood stabilizer in bipolar disorder, particularly in rapid-cycling or lithium-resistant forms. It is a potent cytochrome P450 (CYP3A4, CYP2C9, CYP1A2) inducer, accelerating its own metabolism (auto-induction) and that of many co-administered drugs - a pharmacokinetic property central to understanding its interactions and the need for therapeutic monitoring by serum dosage. In Quebec, it is available as regular tablets (200 mg), controlled-release tablets (Tegretol CR 200 mg and 400 mg) - the CR form offering more stable kinetics and better neurological tolerance - and as an oral suspension. Carbamazepine is the subject of an important pharmacogenomic warning: carriers of the allele HLA-B*15:02 (common in Southeast Asian populations - Thais, Vietnamese, Malaysians, Filipinos, Han Chinese) present a significantly elevated risk of severe cutaneous reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis - NET); genotyping HLA-B*15:02 prior to initiation is recommended in these populations by Health Canada and North American practice guidelines.
Approved indications
- Focal (partial) epilepsy with or without secondary generalization: main and best-established indication - simple focal seizures, focal seizures with altered consciousness (formerly complex partial seizures), secondary generalized tonic-clonic seizures ; first-line antiepileptic for focal epilepsy in adults, according to several guidelines (although new-generation antiepileptics - lamotrigine, levetiracetam - are often preferred in first-line treatment for their better tolerability profile and fewer interactions); ineffective or even aggravating for idiopathic generalized epilepsy (absence, myoclonus - may precipitate myoclonic malaise)
- Essential trigeminal neuralgia (painful tic of the face): historical reference indication - first-line drug treatment for idiopathic trigeminal neuralgia (effective in 70-80 % of cases with significant reduction in frequency and intensity of paroxysmal painful attacks); also used in glosso-pharyngeal neuralgia
- Bipolar disorder - prevention of manic and depressive episodes: second-line mood stabilizer - used as an alternative to or in combination with lithium, particularly in rapid-cycling forms (≥ 4 episodes per year), dysphoric mania and lithium-resistant forms; less effective than lithium in preventing bipolar depressive episodes
- Neuropathic pain (outside official MA but recognized use): painful diabetic neuropathy, postherpetic pain, post-traumatic neuropathy - less frequent use since the arrival of better-tolerated molecules (pregabalin, gabapentin, duloxetine).
- Alcohol withdrawal syndrome (hospital use): used in some severe alcohol withdrawal protocols - reduces risk of epileptic withdrawal seizures; less standardized use than benzodiazepines in North America
Dosage and dosage forms
- Adult epilepsy: gradual initiation - 100 to 200 mg 1 to 2 times a day, increased in 100 to 200 mg increments every 1 to 2 weeks depending on tolerance and efficacy; usual maintenance dose: 400 to 1,600 mg/day in 2 to 4 doses (standard tablets) or 2 doses (Tegretol CR); maximum dose: 1,600 mg/day (or even 2,400 mg/day in exceptional cases and under close supervision)
- Trigeminal neuralgia: initiation at 100 mg twice a day - progressive increase to 200 mg 3 to 4 times a day depending on response; maintenance dose often lower than for epilepsy (400 to 800 mg/day) with attempts at gradual reduction if remission is sustained
- Bipolar disorder: doses similar to epilepsy - 400 to 1,200 mg/day in divided doses; slow titration to improve tolerance
- Tegretol CR (controlled release): taken twice a day - more stable plasma kinetics (lower plasma peak, higher valley concentrations) reducing fluctuations associated with dose-dependent neurological side effects (dizziness, diplopia, ataxia); do not crush or chew CR tablets.
- Taken with meals: improves digestive tolerance and reduces absorption fluctuations; oral bioavailability is 75-85 % (slow absorption, varying according to form)
- Enzymatic autoinduction: serum levels may fall by 25 to 50 % in the first 3 to 5 weeks of treatment due to induction of its own metabolism (CYP3A4) - often requires a dosage increase after the first few weeks to maintain therapeutic levels; new steady state reached in 3 to 4 weeks
ℹ️
Never stop carbamazepine abruptly in an epileptic patient - abrupt withdrawal can trigger a potentially fatal état de mal épileptique. Any change in dosage must be gradual and supervised by the prescribing physician. If you forget to take a dose, take it as soon as possible, unless it is close to the next dose - never double the next dose.
Undesirable effects
| Undesirable effect | Description and management | Frequency |
|---|---|---|
| Diplopia, vertigo, ataxia | Most frequent dose-dependent neurological effects - occur mainly at the start of treatment or when increases are too rapid; drowsiness, sensation of drunkenness, disturbance of equilibrium; reduced by slow titration and switch to Tegretol CR; generally diminishes at steady state | Very common |
| Nausea, vomiting, gastric discomfort | Frequent digestive effects at the start of treatment - alleviated by taking with meals and gradual titration | Common |
| Hyponatremia (SIADH) | Reduced natraemia due to inappropriate ADH secretion - increased risk in the elderly, patients on thiazide diuretics or SSRIs; may cause confusion, headaches, paradoxical epileptic seizures; natraemia measurement recommended on initiation and during monitoring; dosage reduction or discontinuation if natraemia < 125 mmol/L | Common |
| Maculopapular rash | Mild cutaneous rash in 5-10 % of patients - usually occurs within the first 4 weeks; requires immediate medical evaluation to rule out onset of severe reaction (Stevens-Johnson, DRESS); discontinue drug if rash progresses, mucous membranes are affected or fever is present | Common (5-10 %) |
| Transient leukopenia | Moderate reduction in white blood cells (PNN > 1,000/mm³) in the first few weeks - generally benign and transient; regular CBC monitoring; stop if PNN < 1,000/mm³ or platelets < 100,000/mm³. | Common |
| Elevated liver enzymes (GGT, PAL) | Related to enzyme induction - isolated elevations of GGT and PAL very frequent, of no clinical significance in the absence of other hepatic abnormalities; frank hepatotoxicity rare (< 0.1 %) | Very common (mild) |
| Stevens-Johnson Syndrome (SJS) / NET | Severe, potentially fatal cutaneous reaction - epidermal detachment with mucosal involvement; risk strongly associated with the HLA-B*15:02 allele in Asian populations; generally occurs within the first 3 months; dermatological emergency and resuscitation; immediate and definitive discontinuation of carbamazepine | Rare but serious |
| DRESS syndrome | Drug Reaction with Eosinophilia and Systemic Symptoms - fever, widespread rash, lymphadenopathy, hypereosinophilia, visceral involvement (hepatitis, nephritis, pneumopathy); 2 to 8 weeks after initiation; medical emergency - immediate cessation and systemic corticosteroid therapy | Rare but serious |
| Bone marrow aplasia / agranulocytosis | Rare (< 1/50,000 patients) serious hematological complication - fever, severe infections, unexplained bleeding; emergency CBC; immediate arrest and hematological management. | Very rare |
| Teratogenicity | Congenital malformations (spina bifida - risk multiplied by 5 to 10: 0.5-1 % vs 0.03-0.05 % general population), cleft palate, cardiac malformations, delayed neurological development; folic acid supplementation (5 mg/day) before conception and during the first trimester; pregnancy to be planned with the neurologist. | Pregnancy risk |
Major drug interactions
- Powerful inducer of CYP3A4, CYP2C9 and CYP1A2: carbamazepine accelerates the metabolism of a wide range of drugs, reducing their plasma concentrations and efficacy - estrogen-progestin oral contraceptives (reduced contraceptive efficacy - risk of unplanned pregnancy: use non-hormonal or high-dose contraception), oral anticoagulants (warfarin, apixaban, rivaroxaban - reduced anticoagulation), immunosuppressants (ciclosporin, tacrolimus, sirolimus - risk of graft rejection), antiretrovirals (protease inhibitors, non-nucleoside inhibitors), azole antifungals (voriconazole - almost complete inactivation), systemic corticosteroids, thyroid hormones (levothyroxine - TSH monitoring), CYP3A4-metabolized statins (atorvastatin, simvastatin - significant reduction in concentrations)
- Drugs that increase carbamazepine levels (CYP3A4 inhibitors - risk of toxicity): macrolides (erythromycin, clarithromycin - major interaction - caution or substitute azithromycin), azole antifungals (ketoconazole, fluconazole), calcium channel blockers (diltiazem, verapamil), grapefruit juice, isoniazid, valproate (partial inhibition).
- Other antiepileptics: phenytoin, phenobarbital and primidone also induce CYP3A4 and reduce carbamazepine levels; valproate moderately increases carbamazepine levels and may increase levels of carbamazepine epoxide (active and toxic metabolite) without altering total carbamazepine levels - possible neurological toxicity at apparently normal carbamazepine levels; lamotrigine has its concentrations reduced by 40-50 % by carbamazepine
- MAOIs (monoamine oxidase inhibitors): absolute contraindication - risk of hypertensive crisis and serotonin syndrome; minimum 14-day delay between stopping MAOIs and starting carbamazepine
- Lithium: frequent combination in bipolar disorder - possible potentiation of neurotoxic effects (ataxia, confusion) with normal serum levels of both molecules; close clinical monitoring
- Alcohol: potentiates CNS sedation - avoid alcohol consumption while taking carbamazepine
Recommended biological monitoring
- Serum carbamazepine assay : therapeutic reference range 4 to 12 µg/mL (17 to 50 µmol/L) - steady-state assay (after 3 to 5 weeks of stable treatment); trough sampling (just before morning intake) for reproducibility; levels > 12 µg/mL correlate with dose-dependent neurological toxicity (diplopia, ataxia, nystagmus); levels < 4 µg/mL = subtherapeutic; re-evaluate after any dosage change, any added drug interaction, and in the event of recurrence of seizures despite apparently well-managed treatment
- Complete blood count (CBC): before initiation, then every 2 weeks for the first 3 months, then every 3 to 6 months - screening for leukopenia, thrombocytopenia or bone marrow aplasia; discontinue if PNN < 1,500/mm³ or worsen rapidly
- Liver function tests (ALT, ASAT, GGT, PAL, bilirubin): before initiation, then at 1 month, 3 months, then annually - GGT and PAL often elevated by enzyme induction without pathological significance; ALT > 3× normal = dosage reduction or discontinuation
- Natremia: before initiation, then at 1 month and whenever there are any suggestive symptoms (confusion, nausea); close monitoring in the elderly and in patients on diuretics or SSRIs.
- Renal assessment (creatinine, GFR): before initiation; dosage adjustment if severe renal impairment (GFR < 30 mL/min)
- TSH: annual monitoring if long-term treatment - enzymatic induction may reduce free T4 levels and necessitate increased levothyroxine in hypothyroid patients receiving replacement therapy
- HLA-B*15:02 genotyping: recommended before initiation in patients of Asian origin (Thailand, Vietnam, Malaysia, Philippines, South China) - contraindicated if HLA-B*15:02 allele carrier
- Bone density (osteodensitometry): carbamazepine is an inducer of vitamin D metabolism (reduced 25-OH-vitamin D levels) and may lead to osteopenia or osteoporosis in the long term - calcium and vitamin D3 supplementation recommended for all patients on long-term treatment; osteodensitometry recommended after 5 years of treatment
Signs requiring urgent consultation or 911
Dial 911 or go immediately to the emergency room in the event of : progressive skin rash with mucous membrane involvement (mouth, eyes, genitals) accompanied by fever - suggestive of Stevens-Johnson syndrome or DRESS syndrome (discontinue carbamazepine immediately); high fever with sore throat and mouth ulcerations (agranulocytosis) ; acute mental confusion, nausea and muscle cramps in a patient on diuretics (severe hyponatremia); any prolonged seizure (> 5 minutes) or repetition of seizures without regaining consciousness (état de mal épileptique).
For follow-up of carbamazepine therapy, prescription of monitoring tests or re-evaluation of efficacy and tolerance, Clinique Omicron offers consultations in our Quebec branches, as well as via telemedicine. To book an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron's physicians monitor patients on carbamazepine, prescribing the required monitoring tests (serum levels, CBC, liver function tests, natraemia), assessing drug interactions and referring patients to partner neurologists and psychiatrists, depending on the clinical context. Consultations are available in our Quebec branches, as well as via telemedicine across the province. To book an appointment, visit cliniqueomicron.ca.
The contents of this page are provided for information purposes only and do not replace the advice of a qualified healthcare professional. No medication should be initiated, modified or discontinued without the advice of the prescribing physician. Never discontinue carbamazepine abruptly without medical supervision.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.